BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration
Shots:
- In the P-I SPICE study- the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types
- PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21
- NG-641 is a tumor re-engineering product using PsiOxus’ T-SIGn platform based upon the enadenotucirev vector while Opdivo is a PD-1 immune checkpoint inhibitor- designed to harness the body’s own immune system to help restore anti-tumor immune response
Ref: Businesswire | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com